{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-004420","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2023-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.837569+00:00","generated_at":"2026-06-17T06:26:36.877016+00:00","sec_items":["3.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Tonix Pharmaceuticals receives Nasdaq non-compliance notice and prioritizes CNS pipeline","bullets":["Received Nasdaq notice on March 31, 2023, for non-compliance with $1 minimum bid price; has 180 days until September 27, 2023 to regain compliance.","Reallocating resources to focus on mid- and late-stage CNS programs: fibromyalgia (TNX-102 SL), depression (TNX-601 ER), migraine (TNX-1900), cocaine intoxication (TNX-1300).","Delaying start of Phase 3 PTSD study in Kenya and discontinuing enrollment in Phase 2 Long COVID study; ~60 patients to be followed, topline data expected Q3 2023.","Cash and cash equivalents approximately $120.2 million as of December 31, 2022; key 2023 milestones include interim Phase 3 RESILIENT data in Q2 and topline data in Q4.","Deprioritizing COVID-19 related programs: anti-COVID antibodies (TNX-3600, -3800, -4100) and vaccines (TNX-1800, -1850); continuing TNX-801 and broad-spectrum antivirals."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-004420","json":"https://secwatch.observer/filing/0001387131-23-004420.json","markdown":"https://secwatch.observer/filing/0001387131-23-004420.md","text":"https://secwatch.observer/filing/0001387131-23-004420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123004420/0001387131-23-004420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123004420/tnxp-8k_033123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:26:36.877016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75195545050a7e48ac744cb5a3b2a26b05c09283","claim":"Tonix Pharmaceuticals Holding Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"March 31, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq listing rules, the Company has been provided a period of 180 calendar days, or until Septem","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123004420/0001387131-23-004420-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}